ASO Experience and Scientific Excellence Driving the n-Lorem Discovery and Development Platform 

Julie Douville, Ph.D., Executive Director of ASO Discovery and Development at n-Lorem, presents at the 2023 Nano-rare Patient Colloquium.
Every new patient represents a novel ASO discovery and development program. The essence of science is uncertainty and the process of discovering a novel medicine is complex and arduous, even for ASOs. At n-Lorem, we are industrializing the treatment of nano-rare patients because we believe that each patient deserves the very best ASO that we can discover and develop. In this presentation, we provide data driven examples of hard choices that only expertise, a deep understanding of ASOs and decades of experience developing ASOs into a powerful drug discovery platform, can inform. Our patients deserve nothing short of the best that we can do.